Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium phosphate dibasic anhydrous + sodium phosphate monobasic is an **oral small-molecule osmotic laxative combination** used primarily for **cleansing of the colon before colonoscopy in adults**. The product is marketed under brand names including **OsmoPrep** and **Visicol**. Its laxative effect is mediated by the **osmotic activity of phosphate salts in the intestinal lumen**, which draws water into the bowel, promotes catharsis, and facilitates bowel evacuation rather than acting through a discrete receptor or enzyme target. This combination has been developed and marketed for bowel preparation, while related sodium phosphate formulations administered by injection are used separately as phosphorus replacement products for hypophosphatemia and should not be conflated with the oral tablet bowel-prep product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate dibasic anhydrous + sodium phosphate monobasic.